ethyl 6-chloro-4-((4-methyl-3-nitrophenyl)amino)quinoline-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 6-chloro-4-((4-methyl-3-nitrophenyl)amino)quinoline-3-carboxylate
• 英文别名: Ethyl 6-chloro-4-(4-methyl-3-nitroanilino)quinoline-3-carboxylate；ethyl 6-chloro-4-(4-methyl-3-nitroanilino)quinoline-3-carboxylate
• 化学式: C₁₉H₁₆ClN₃O₄
• 分子量: 385.807
• InChiKey: ACMVOBPXZNESJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  97
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 6-chloro-4-((4-methyl-3-nitrophenyl)amino)quinoline-3-carboxylate 在 manganese(IV) oxide 、 sodium tetrahydroborate 、 tin(II) chloride dihdyrate 、 potassium carbonate 作用下， 以 乙醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 21.0h， 生成 1-(3-Amino-4-methylphenyl)-9-chlorobenzo[h][1,6]naphthyridin-2-one
  参考文献：
  名称：

  [EN] BONE MARROW ON X CHROMOSOME KINASE (BMX) INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE KINASE MOELLE OSSEUSE SUR CHROMOSOME X (BMX) ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2014063054A8
• 作为产物：
  描述：

  4,6-二氯喹啉-3-羧酸乙酯 、 4-甲基-3-硝基苯胺 以 1,4-二氧六环 为溶剂， 反应 4.0h， 以76%的产率得到ethyl 6-chloro-4-((4-methyl-3-nitrophenyl)amino)quinoline-3-carboxylate
  参考文献：
  名称：

  [EN] HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES
  [FR] INHIBITEURS CIBLANT L'HÔTE DU VIRUS DE LA DENGUE ET D'AUTRES VIRUS

  摘要：

  提供了化合物式（I）-（III）的新型抗病毒化合物：（I）（II）（III）。这些创新化合物，其药物组合物和包括这些创新化合物的工具包可用于预防和治疗由病毒引起的传染病，例如黄热病毒科病毒（例如登革热病毒（DENY），昆明病毒，日本脑炎病毒，口疮病毒（VSV），单纯疱疹病毒1型（HSV-1），人类巨细胞病毒（HCMV），脊髓灰质炎病毒，胡尼恩病毒，埃博拉病毒，马尔堡病毒（MARV），拉沙热病毒（LASV），委内瑞拉马蹄热病毒（VEEV）或裂谷热病毒（RVFV）。

  公开号：

  WO2013154778A1

文献信息

• Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10000483B2

  公开（公告）日：2018-06-19

  The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds of Formula (I) or (II), or compositions thereof, for treating or preventing a wide range of diseases (e.g., proliferative diseases (e.g., cancers, benign neoplasms, angiogenesis, inflammatory diseases, autoimmune diseases) and metabolic diseases (e.g., diabetes (e.g., type 2 diabetes, gestational diabetes)) in a subject. Treatment of a subject with a disease using a compound of Formula (I) or (II), or compositions thereof, may downregulate the expression and/or inhibit the activity of a kinase (e.g., a tyrosine kinase, such as a Tec kinase, in particular, bone marrow on X chromosome kinase (BMX)), and therefore, suppress tyrosine kinase singling in the subject.

  本发明提供了新颖的式(I)化合物及其药学上可接受的盐、溶液剂、水合物、多晶型、共晶体、同系物、立体异构体、同位素标记的衍生物、原药及其组合物。还提供了涉及式（I）或（II）化合物或其组合物的方法和试剂盒，用于治疗或预防受试者的多种疾病（如增殖性疾病（如癌症、良性肿瘤、血管生成、炎症性疾病、自身免疫性疾病）和代谢性疾病（如糖尿病（如 2 型糖尿病、妊娠糖尿病））。使用式(I)或(II)化合物或其组合物治疗患有疾病的受试者，可下调激酶（如酪氨酸激酶，如Tec激酶，特别是X染色体上的骨髓激酶（BMX））的表达和/或抑制其活性，从而抑制受试者体内的酪氨酸激酶单体。
• Structure–Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent
  作者：Yanke Liang、Melissanne de Wispelaere、Margot Carocci、Qingsong Liu、Jinhua Wang、Priscilla L. Yang、Nathanael S. Gray

  DOI：10.1021/acsmedchemlett.7b00008

  日期：2017.3.9

  Here we report the structure activity relationship (SAR) investigations of QL-XII-47 (QL47), a compound that possesses broad-spectrum antiviral activity against dengue virus and other RNA viruses. A medicinal chemistry campaign initiated from QL47, a previously reported covalent BTK inhibitor, to derive YKL-04-085, which is devoid of any kinase activity when screened against a panel of 468 kinases and with improved pharmacokinetic properties. Both QL47 and YKL-04-085 are potent inhibitors of viral translation and exhibit cellular antiviral activity at 35-fold lower concentrations relative to inhibition of host-cell proliferation.
• BONE MARROW ON X CHROMOSOME KINASE (BMX) INHIBITORS AND USES THEREOF
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20150246913A1

  公开（公告）日：2015-09-03

  The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds of Formula (I) or (II), or compositions thereof, for treating or preventing a wide range of diseases (e.g., proliferative diseases (e.g., cancers, benign neoplasms, angiogenesis, inflammatory diseases, autoimmune diseases) and metabolic diseases (e.g., diabetes (e.g., type 2 diabetes, gestational diabetes)) in a subject. Treatment of a subject with a disease using a compound of Formula (I) or (II), or compositions thereof, may downregulate the expression and/or inhibit the activity of a kinase (e.g., a tyrosine kinase, such as a Tec kinase, in particular, bone marrow on X chromosome kinase (BMX)), and therefore, suppress tyrosine kinase singling in the subject.